Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Emerging Techniques in Brain Tumor Imaging: What Radiologists Need to Know.

Kim M, Kim HS.

Korean J Radiol. 2016 Sep-Oct;17(5):598-619. doi: 10.3348/kjr.2016.17.5.598. Epub 2016 Aug 23. Review.

2.
3.

Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.

Atochina-Vasserman EN, Abramova E, James ML, Rue R, Liu AY, Ersumo NT, Guo CJ, Gow AJ, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54. doi: 10.1152/ajplung.00262.2015. Epub 2015 Oct 2.

PMID:
26432869
4.

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Zhao Y, Adjei AA.

Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22. Review.

5.

Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.

Conti L, Ruiu R, Barutello G, Macagno M, Bandini S, Cavallo F, Lanzardo S.

Biomed Res Int. 2014;2014:534969. doi: 10.1155/2014/534969. Epub 2014 Jun 3. Review.

6.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.

Nielsen T, Wittenborn T, Horsman MR.

Pharmaceutics. 2012 Nov 7;4(4):563-89. doi: 10.3390/pharmaceutics4040563.

7.

Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model.

Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM, Gu YH.

Oncol Lett. 2013 Jul;6(1):69-74. Epub 2013 May 14.

8.

Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.

Jia Q, Xu J, Jiang W, Zheng M, Wei M, Chen J, Wang L, Huan Y.

Int J Med Sci. 2013;10(2):110-8. doi: 10.7150/ijms.5123. Epub 2012 Dec 28.

9.

Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer.

Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE.

Magn Reson Med. 2012 Jul;68(1):261-71. doi: 10.1002/mrm.23205. Epub 2011 Nov 29.

10.

Novel ultrasound and DCE-MRI analyses after antiangiogenic treatment with a selective VEGF receptor inhibitor.

Watson KD, Hu X, Lai CY, Lindfors HA, Hu-Lowe DD, Tuthill TA, Shalinsky DR, Ferrara KW.

Ultrasound Med Biol. 2011 Jun;37(6):909-21. doi: 10.1016/j.ultrasmedbio.2011.03.001. Epub 2011 Apr 30.

11.

Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.

Canu B, Fioravanti A, Orlandi P, Di Desidero T, Alì G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, Bocci G.

Neoplasia. 2011 Mar;13(3):217-29.

12.

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H.

Invest New Drugs. 2012 Jun;30(3):1055-64. doi: 10.1007/s10637-011-9637-1. Epub 2011 Feb 8.

13.

A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: I. Simulations.

Schabel MC, Fluckiger JU, DiBella EV.

Phys Med Biol. 2010 Aug 21;55(16):4783-806. doi: 10.1088/0031-9155/55/16/011. Epub 2010 Aug 3.

14.

Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions.

Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, Wickline SA.

Angiogenesis. 2010 Jun;13(2):189-202. doi: 10.1007/s10456-010-9166-0. Epub 2010 Apr 22. Review.

15.

Molecular imaging and targeted therapies.

Morse DL, Gillies RJ.

Biochem Pharmacol. 2010 Sep 1;80(5):731-8. doi: 10.1016/j.bcp.2010.04.011. Epub 2010 Apr 21. Review.

16.

DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.

Kim H, Folks KD, Guo L, Stockard CR, Fineberg NS, Grizzle WE, George JF, Buchsbaum DJ, Morgan DE, Zinn KR.

Mol Imaging Biol. 2011 Feb;13(1):94-103. doi: 10.1007/s11307-010-0320-2.

17.

Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.

Rosen LS, Ashurst HL, Chap L.

Oncologist. 2010;15(3):216-35. doi: 10.1634/theoncologist.2009-0145. Epub 2010 Mar 3. Review.

18.

Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon.

Agrawal G, Su MY, Nalcioglu O, Feig SA, Chen JH.

Cancer. 2009 Apr 1;115(7):1363-80. doi: 10.1002/cncr.24156.

19.

Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.

Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, Kurland BF, Lehman CD, Mankoff DA.

Acad Radiol. 2008 Oct;15(10):1246-54. doi: 10.1016/j.acra.2008.03.019.

20.

Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.

Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, Lanza GM.

FASEB J. 2008 Dec;22(12):4179-89. doi: 10.1096/fj.08-112060. Epub 2008 Aug 12.

Items per page

Supplemental Content

Write to the Help Desk